Daratumumab-Based Triplet Therapy Shows Benefits for Relapsed/Refractory Multiple Myeloma
Results from a recent real-world analysis suggest possible benefits with early use of daratumumab-based t...
Read moreResults from a recent real-world analysis suggest possible benefits with early use of daratumumab-based t...
Read moreCancer Action Now was launch on May 24, an alliance of 28 health care organizations, which includes Myelo...
Read moreMyeloma Canada, along with 24 signatories, wrote a letter to the Federal Health Minister, Jean-Yves Duclo...
Read moreThis past month along with the CANcertainty coalition, Myeloma Canada continued to advocate for the needs...
Read moreOn Feb 15, All.Can Canada launched a new report which highlights where improvements are needed in cancer...
Read moreThe CADTH Therapeutic Review of treatments for transplant-ineligible multiple myeloma patients represents...
Read moreJoin our community and sign up for our newsletter.